

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Which anatomical sites should be sampled for screening of methicillin-resistant *Staphylococcus aureus* carriage by culture or by rapid PCR test?

Authors: Senn L, Basset P, Nahimana I, Zanetti G, Blanc DS

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Year: 2012 Feb

Volume: 18

Issue: 2

Pages: E31-3

DOI: 10.1111/j.1469-0691.2011.03724.x

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

1 **Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in Switzerland:**
2 **sampling only invasive isolates does not allow a representative description of the local**
3 **diversity of clones**

4 L. Senn ¹, P. Basset ¹, G. Greub ², G. Prod'hom ², R. Frei ³, R. Zbinden ⁴, V. Gaia ⁵, C.
5 Balmelli ⁶, G. E. Pfyffer ⁷, K. Mühlemann ⁸, G. Zanetti ¹, D. S. Blanc ¹

6 ¹Service of Hospital Preventive Medicine, ²Institute of Microbiology, Lausanne University
7 Hospital, ³Clinical Microbiology, University Hospital Basel, ⁴Institute of Medical
8 Microbiology, University of Zurich, ⁵Cantonal Institute of Microbiology, Bellinzona, ⁶Ente
9 Ospedaliero Cantonale Ticino, Service of Hospital Epidemiology, ⁷Department of Medical
10 Microbiology, Center for Laboratory Medicine, Luzerner Kantonsspital, ⁸Institute for
11 Infectious Diseases, University of Bern, Switzerland.

12

13 Key words: MRSA surveillance, molecular epidemiology, DLST typing.

14

15 Corresponding author:

16 Laurence Senn, MD

17 Service of Hospital Preventive Medicine,

18 Lausanne University Hospital

19 CH-1011 Lausanne, Switzerland

20 E-mail: Laurence.Senn@chuv.ch.

21 Phone: +41 21 314 75 85, Fax: +41 21 314 02 62

22

23 **Abstract**

24 We conducted a molecular study of MRSA isolated in Swiss hospitals, including the first five
25 consecutive isolates recovered from blood cultures and the first ten isolates recovered from
26 other sites in newly identified carriers. Among 73 MRSA isolates, 44 different Double Locus
27 Sequence Typing (DLST) types and 32 *spa* types were observed. Most isolates belonged to
28 the NewYork/Japan, the UK-EMRSA-15, the South German and the Berlin clones. In a
29 country with a low to moderate MRSA incidence, inclusion of non-invasive isolates allowed a
30 more accurate description of the diversity.

31

32 **Research note**

33 According to the European Antimicrobial Resistance Surveillance Network (EARS-Net) data
34 (www.ecdc.europa.eu), the proportion of invasive *Staphylococcus aureus* isolates that were
35 found to be methicillin-resistant (MRSA) in European countries varied from below 5% to
36 more than 50% in 2010. Switzerland is not included in the EARS-Net but has a national
37 surveillance program for antibiotic resistance (www.anresis.ch). Overall the proportion of
38 MRSA in clinical specimens was 9% in 2010 and 8% in 2011, varying from 4% in Central
39 Switzerland to 14% in Western Switzerland.

40 Clonal lineages can be identified by molecular typing. Thus it is possible to follow the
41 epidemiology and spread of major clones [1, 2]. A molecular epidemiological analysis
42 conducted in 2006-2007 showed that MRSA *spa* types had a predominantly regional
43 distribution in Europe [3]. Switzerland was not included in this study and no nation-wide
44 molecular data were available since the last national study conducted in 1997 [4]. The
45 objective of the present study was to assess the current molecular epidemiology of MRSA in
46 Swiss hospitals.

47 Between January and June 2011, we conducted a survey of MRSA isolates collected in five >
48 500-bed Swiss hospitals (Basel, Bern, Lausanne, Luzern, and Zürich). Hospitals from the
49 Italian-speaking region (Ticino) were also included and considered as one center.
50 Participating hospitals had an incidence of new MRSA cases varying from below 1 to 18 per
51 1000 admissions (Table 1). Laboratories of participating centers were asked to collect up to
52 five consecutive MRSA isolates from blood cultures in individual patients and the first ten
53 consecutive MRSA isolates from clinical samples other than blood or from screening samples
54 in newly identified MRSA carriers (one isolate per carrier). All isolates were sent to one
55 reference center (Lausanne). Molecular analysis of MRSA strains was done by Double Locus
56 Sequence Typing (DLST, a method based on the analysis of the highly variable regions of the
57 *clfB* and *spa* genes) [5], *spa*-typing [6], and SCC*mec* typing [7]. The presence of Pantone-
58 Valentine leukocidin (PVL) genes was also investigated as described previously [8].

59 A total of 74 isolates were sent to the reference center: 14 isolates from blood cultures (zero to
60 five per center) and 60 isolates from clinical or screening samples (ten per center). One isolate
61 was found to be *mecA* negative (probable borderline oxacillin-resistant *S. aureus*; BORSA)
62 and was excluded from the analysis. Depending on the hospitals' MRSA incidence, nine days
63 to 3 months were needed to obtain isolates from ten newly identified patients.

64 Median age of patients was 63 years (range 1 to 99). Forty-eight (66%) were males. At the
65 time of bacteraemia or first MRSA identification, 35 patients were hospitalized in wards, 7 in
66 ICUs, 21 in emergency rooms or outpatient clinic; information was missing for 10 patients.
67 Among the 14 patients with MRSA bacteraemia, 4 (29%) died within 14 days (all-cause
68 mortality); ten episodes (71%) were hospital-onset bacteraemia.

69 Among the 73 MRSA isolates, 44 different DLST types (3 to 11 per hospital) and 32 *spa*
70 types (2 to 9 per hospital) were observed (Table 1). Only 10 DLST types were shared by more

71 than one patient (2 to 12 patients). Nine different DLST types were found among the 14
72 MRSA strains isolated from blood cultures, whereas 38 different DLST types were found in
73 the 59 other isolates.

74 DLST types were compared to typing data of international clones [7, 8]. At least 62 out of 74
75 (84%) MRSA isolates were related to 11 international clones (Table 2). Most of them
76 belonged to the New York/Japan (ST5/105-SCC*mec* II- PVL neg; n=16), the UK-EMRSA-15
77 (ST22-IV-neg; n=15), the South German (ST228-I-neg; n=14) and the Berlin (ST45-IV-neg;
78 n=4) clones. These data are consistent with the major international clones recovered in Europe
79 [2]. However, the major clones currently observed in Swiss hospitals were different than those
80 observed in 1997, except for the Berlin clone [9]. This illustrates a change in the molecular
81 epidemiology of MRSA in Switzerland.

82 The genetic diversity encountered within each center varied according to the local
83 epidemiology of MRSA. In the hospital with the highest MRSA incidence, 12 out of 15
84 isolates had the same DLST type indicating a large clonal outbreak in this center. In contrast,
85 hospitals with a lower incidence showed a higher genetic diversity, suggesting a non-clonal
86 spread of MRSA in these centers.

87 In this study, MRSA isolates were collected in few eligible centers with a low to moderate
88 MRSA incidence during a limited period of time. Thus, only few invasive isolates were
89 analyzed. Inclusion of non-invasive isolates allowed more isolates to be collected and to
90 obtain a more accurate description of the diversity. Moreover, consecutive isolates were
91 collected and the diversity observed in a hospital facing a clonal MRSA outbreak (such as
92 center 1) was probably not representative of the real diversity observed year-round.

93 This study suggests that a national surveillance program could be easily implemented.
94 Molecular analysis of ten isolates per center per year recovered throughout the whole year

95 should reflect the diversity of locally circulating MRSA clones. Only isolates of newly
96 diagnosed MRSA cases (carriers or infected patients) should be included to better describe the
97 incidence of circulating clones at the present time. DLST method allows the simultaneous
98 analysis of 96 isolates in three days for an estimated cost of 20 euros per isolate and is
99 therefore well suited for that purpose.

100 In conclusion, this study represents a recent update on the genetic diversity of MRSA
101 observed in Switzerland. At least 11 international clones were recovered from the six
102 participating centers. The small number of invasive isolates recovered in centers with a low
103 MRSA incidence would not have allowed an accurate description of the local diversity.
104 Adding none-invasive isolates represented a good alternative in settings with low MRSA
105 incidence.

106

107 **Acknowledgements**

108 The Swiss study was performed concurrently with a second European study on the molecular
109 epidemiology of invasive *S.aureus*. We thank Hajo Grundmann and colleagues for the
110 organization of the study at the European level.

111 We are also grateful to all laboratories that provided us with MRSA isolates and to Caroline
112 Choulat for technical assistance.

113 This study was presented in part at the 22th European Congress of Clinical Microbiology and
114 Infectious Diseases (ECCMID), London, UK, April 2012.

115

116 **Reference List**

117

- 118 1 Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen:
119 Molecular evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*.
120 *Lancet Infect Dis.* 2002; **2**: 180-189.
- 121 2 Grundmann H, Aanensen DM, van den Wijngaard CC, et al. Geographic distribution
122 of *Staphylococcus aureus* causing invasive infections in europe: A molecular-
123 epidemiological analysis. *PLoS Med.* 2010; **7**: e1000215.
- 124 3 Blanc DS, Pittet D, Ruef C, et al. Molecular epidemiology of predominant clones and
125 sporadic strains of methicillin resistant *Staphylococcus aureus* in switzerland and
126 comparison with european epidemic clones. *Clin Microbiol Infect.* 2002; **8**: 419-426.
- 127 4 Kuhn G, Francioli P, Blanc DS. Double-locus sequence typing using clfb and spa, a
128 fast and simple method for epidemiological typing of methicillin-resistant
129 *Staphylococcus aureus*. *J Clin Microbiol.* 2007; **45**: 54-62.
- 130 5 Kondo Y, Ito T, Ma XX, et al. Combination of multiplex pcrs for staphylococcal
131 cassette chromosome mec type assignment: Rapid identification system for mec, ccr,
132 and major differences in junkyard regions. *Antimicrob Agents Chemother.* 2007; **51**:
133 264-274.
- 134 6 Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of panton-valentine
135 leukocidin-producing *Staphylococcus aureus* in primary skin infections and
136 pneumonia. *Clin Infect Dis.* 1999; **29**: 1128-1132.
- 137 7 Basset P, Hammer NB, Kuhn G, Vogel V, Sakwinska O, Blanc DS. *Staphylococcus*
138 *aureus* clfb and spa alleles of the repeat regions are segregated into major
139 phylogenetic lineages. *Infect Genet Evol.* 2009; **9**: 941-947.

140 8 Basset P, Senn L, Prod'hom G, et al. Usefulness of double locus sequence typing
141 (DLST) for regional and international epidemiological surveillance of methicilin-
142 resistant *Staphylococcus aureus*. *Clin Microbiol Infect*. 2010; **16**: 1289-1296.

143 9 Blanc DS, Petignat C, Wenger A, et al. Changing molecular epidemiology of
144 methicillin-resistant *Staphylococcus aureus* in a small geographic area over an eight-
145 year period. *J Clin Microbiol*. 2007; **45**: 3729-3736.

146

147

148 **Table 1. Epidemiological data of participating centers**

Center	1	2	3	4	5	6	Total
Admissions (n)*	36112	37958	31149	34630	38924	36454	215227
New MRSA cases/1000 admissions*	18.05	0.63	1.09	1.24	1.95	1.34	4.15
Bacteremia due to MRSA/1000 adm.*	1.27	0.11	0.06	0.06	0.18	0.03	0.29
MRSA isolates (n)	15	13	10	10	15	10	73
Blood cultures	5	3	0	1	5	0	14
Other**	10	10	10	9	10	10	59
DLST types (n)	3	9	10	10	11	9	44
<i>spa</i> types (n)	2	9	9	8	8	9	32

* in 2010

** including screening samples

149

Table 2. International clones recovered in Switzerland.

International clone (ST, SCCmec, PVL)	Centers	DLST types (n)	spa types
New York/Japan (ST5/105-II-neg)	1, 2, 3, 4, 5, 6	2-2(9)	t002
		2-80(3)	t003
		2-414(1)	t586
		586-2(1)	t002
		665-80(1)	t003
		666-80(1)	t003
UK EMRSA-15 (ST22-IV-neg)	1, 4, 5	32-346(2)	t8849
		32-211(2)	t515
		32-623(2)	t2231
		32-627(1)	t2440
		32-341(1)	t3130
		32-626(3)	t4640
		32-628(1)	t7478
		251-211(1)	t515
		663-211(1)	t515
		664-211(1)	t515
South German (ST228-I-neg)	1, 2, 6	4-4(12)	t041
		4-338(1)	t579
		4-618(1)	ND
Berlin (ST45-IV-neg)	2, 3, 4, 6	1-198(1)	t050
		121-198(1)	t050
		641-37(1)	t015
		389-11(1)	t065
European CA-MRSA (ST80-IV-pos)	4, 6	7-26 (2)	t044
		646-26 (1)	t044
WA-MRSA-2 (ST88-IV-pos)	2, 3	69-63 (1)	t786
		604-409 (1)	t692
		653-287 (1)	t690
Lyon (ST8-IV-neg)	3	658-3 (1)	t008
		100-3 (1)	t008
Brazilian (ST239-IIImerc.-neg)	5	660-30 (2)	t037
WA-MRSA-1 (ST1-IV-neg)	4	5-46 (1)	t127
Southwest pacific (ST30-IV-pos)	2	51-94 (1)	t318
Livestock associated (ST398-V-neg)	4	245-339 (1)	t034

ST = sequence type according to the multilocus sequence typing (MLST) scheme

n = number of isolates

ND = not determined